Incorporating Type-2 inflammation status with clinical diagnosis and transcriptomics data in asthma risk classification

Zi Ye; Solomon W Harrar; Joseph Beyene; Tesfaye B Mersha

doi:10.1016/j.anai.2025.06.029

Incorporating Type-2 inflammation status with clinical diagnosis and transcriptomics data in asthma risk classification

Ann Allergy Asthma Immunol. 2025 Jun 26:S1081-1206(25)00321-7. doi: 10.1016/j.anai.2025.06.029. Online ahead of print.

Authors

Zi Ye¹, Solomon W Harrar², Joseph Beyene³, Tesfaye B Mersha⁴

Affiliations

¹ Department of Mathematics, Lehigh University, PA, USA. Electronic address: Zi421@lehigh.edu.
² Dr. Bing Zhang Department of Statistics, University of Kentucky, KY, USA. Electronic address: solomon.harrar@uky.edu.
³ Institute of Health Policy, Management and Evaluation, McMaster University, ON, Canada. Electronic address: beyene@mcmaster.ca.
⁴ Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH, USA. Electronic address: Tesfaye.Mersha@cchmc.org.

PMID: 40581211
DOI: 10.1016/j.anai.2025.06.029

Abstract

bronchial hyperresponsiveness (BHR), Immunoglobulin (IgE), skin prick test (SPT), T helper 2 (Th2), interleukin (IL), Type 2 inflammation (Th2), Area Under the Curve (AUC), Receiver Operating Characteristic (ROC), Genes-Environments and Admixture in Latino Americans (GALA II).

Keywords: Biomarker; Th2-high; Th2-low; risk classification; transcriptomics.